Is the US prepared to deal with another pandemic or widespread health crisis?

No, the US is better prepared in some key areas than before COVID-19 but remains inadequately ready overall for another major pandemic or widespread health crisis, according to government reports, bipartisan commissions, GAO assessments, and expert analyses. Significant progress exists in stockpiles, surveillance, medical countermeasure platforms, and coordination structures, yet persistent gaps in workforce, funding sustainability, full implementation of lessons learned, leadership continuity, testing strategies, and supply chains leave vulnerabilities.[1]

Areas of Improvement

Post-COVID investments yielded tangible gains:

•Strategic National Stockpile (SNS): Dramatically restocked. It holds ~70 times the pre-pandemic N95 respirators, 34 times the gloves, 50 times the isolation gowns, and 10 times the ventilators. It has supported responses to H5N1 bird flu (PPE and antivirals), mpox (over 1 million vaccine vials and treatments), and other events. Efforts continue to improve domestic manufacturing signals and place assets closer to jurisdictions.[2]

•Surveillance and data: Electronic case reporting expanded from under 200 healthcare facilities in 2020 to over 45,000–48,000 by 2024. Over 80% of hospital EDs provide syndromic surveillance data. Wastewater monitoring and other tools improved for early detection (e.g., COVID, mpox, flu). “One CDC” data platforms and partnerships aim for better integration.[3]

•Medical countermeasures and R&D: mRNA and other platforms enable faster vaccine/therapeutic development (e.g., investments for H5N1-adaptable vaccines; stockpiling doses). BARDA and related efforts advanced diagnostics, treatments, and “warm base” lab capacity. Global contributions include the Pandemic Fund (US-backed grants mobilizing billions for dozens of countries) and vaccine sharing.[4]

•Structures and planning: The Office of Pandemic Preparedness and Response Policy (OPPR) was created (via PREVENT Pandemics Act) as a White House coordinating body. A National Biodefense Strategy, Global Health Security Strategy (2024), and Biden-era “roadmap”/playbooks outlined responses. CDC and ASPR enhanced quality controls, lab partnerships, and exercises.[2]

These steps helped end the acute COVID emergency phase, supported mpox and H5N1 responses, and built some resilience. Vaccination and testing scale-up during COVID saved millions of lives/hospitalizations per analyses.[2]

Persistent Gaps and Challenges

Watchdogs and experts highlight shortfalls that could hinder a rapid, effective response:

•Workforce shortages: State/local public health needs ~80,000 additional full-time equivalents (an ~80% increase) just for foundational services. Shortages hit epidemiology, nursing, informatics, leadership, and rural areas hard; COVID exacerbated burnout and turnover. Gaps limit disease investigation, surge capacity, and routine functions. Federal/state efforts (training, loan repayment) help but are insufficient for sustained readiness.[5]

•Incomplete lessons learned and coordination: GAO has tracked hundreds of COVID-related recommendations; roughly half (e.g., ~220 of 428+ as of mid-2024) remained open into 2025, including on HHS leadership of emergencies (HHS remains on GAO’s High-Risk List), testing strategies, SNS request/receipt processes with states, IT systems, isolation/quarantine planning, and supply chain resilience. No comprehensive national diagnostic testing strategy fully exists despite expert input. Interagency and federal-state coordination issues persist.[6]

•Leadership and institutional continuity: OPPR peaked at ~15 staff but was effectively emptied in 2025 under the incoming administration (staff departures, resignations); it was later minimally restaffed (1–2 people reported in mid-2026 amid outbreaks). Political shifts risk reversing gains, with reports of program cuts, delayed priorities, or focus changes (e.g., amid H5N1). Bipartisan Commission on Biodefense (2024 National Blueprint) stressed fragmented efforts, growing biological threats (natural, accidental, deliberate), and the need for top-level sustained leadership—warning the US remains “dangerously vulnerable” and that fuller prior recommendations could have mitigated COVID’s toll.[1]

•Funding, stockpiles beyond PPE, and supply chains: COVID supplemental funds largely ended (e.g., Bridge Access vaccine program), creating cliffs. Domestic PPE/medical manufacturing has improved but remains vulnerable to shocks; reusable respirators and broader surge capacity lag. SNS guidance and state coordination need updates. Broader biodefense funding faces pressures.[7]

•Other risks: Ongoing H5N1 (animal spread, limited human cases) tests systems, with critiques of testing volume/surveillance aggressiveness. Misinformation, equity issues, hospital surge capacity, and international dependencies (e.g., WHO dynamics) add complexity. Climate and antimicrobial resistance amplify threats.

The Bipartisan Commission and others note biological threats are real and growing; “on-again/off-again” funding and attention leave the country reactive rather than proactive.[8]

Bottom Line

The US has stronger tools than in early 2020—better stocked warehouses, faster data flows, platform technologies, and some institutional memory—and has demonstrated competence in smaller responses (mpox, H5N1 support). However, chronic underinvestment in the public health workforce and infrastructure, incomplete adoption of GAO and commission recommendations, fragile political/funding continuity, and coordination shortfalls mean it is not fully prepared for a high-consequence novel pathogen or large-scale crisis on the scale of (or worse than) COVID-19. Experts emphasize that sustained, bipartisan investment, full implementation of reforms, robust leadership, and domestic capacity-building are essential to close the gap. Preparedness is a continuous process, not a one-time fix; current trajectories leave substantial risk.

Citations (8)

1biodefensecommission.orgNonprofits and think tanks
https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
Backs: “Significant progress exists in stockpiles, surveillance, medical countermeasure platforms, and coordination structures, yet persistent gaps in workforce, funding sustainability, full implementation of lessons learned, leadership continuity, testing strategies, and supply chains leave vulnerabilities.”
2archives.govGovernment
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “Efforts continue to improve domestic manufacturing signals and place assets closer to jurisdictions.”
3cdc.govGovernment
https://www.cdc.gov/washington/testimony/2024/t20241114.htm
Backs: ““One CDC” data platforms and partnerships aim for better integration.”
4archives.govGovernment
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2024/12/11/fact-sheet-biden-harris-administration-releases-global-health-security-annual-report-demonstrating-the-impact-of-united-states-leadership-and-investments/
Backs: “Global contributions include the Pandemic Fund (US-backed grants mobilizing billions for dozens of countries) and vaccine sharing.”
5umn.eduAcademic
https://www.cidrap.umn.edu/public-health/gao-public-health-workforce-shortage-undermines-ability-respond-outbreaks-other
Backs: “Federal/state efforts (training, loan repayment) help but are insufficient for sustained readiness.”
6stimson.orgNonprofits and think tanks
https://www.stimson.org/2024/prepare-for-the-next-biothreat-now/
Backs: “No comprehensive national diagnostic testing strategy fully exists despite expert input. Interagency and federal-state coordination issues persist.”
7govexec.comNews and mediaquality 0.87
https://www.govexec.com/oversight/2024/05/strategic-national-stockpile-ready-next-emergency-gao-says-no/396567/
Backs: “SNS guidance and state coordination need updates. Broader biodefense funding faces pressures.”
8biodefensecommission.orgNonprofits and think tanks
https://biodefensecommission.org/wp-content/uploads/2024/05/National-Blueprint-for-Biodefense-2024_final_.pdf
Backs: ““on-again/off-again” funding and attention leave the country reactive rather than proactive.”